Value
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 0.1 |
| P/S | 9.2 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 2.9 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 37.6x
- ▸PEG: 0.23
MDXG · Why this verdict
Why MiMedx Group (MDXG) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
MiMedx offers an unusually favorable risk-reward setup and a 3-of-4 earnings beat streak, but a sharp revenue decline and a death-cross-confirmed technical downtrend keep the position squarely in speculative, recovery-dependent territory.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
MiMedx's revenue is declining sharply, down 33% YoY, and the Rule of 40 combined growth-plus-margin metric registers a failing reading. Growth breakdown | Revenue growth should turn positive within a few quarters. | →Stable |
| CounterStrong cash conversion and a solid Piotroski F-Score of 7 out of 9 suggest the company is still generating cash efficiently even amid the top-line contraction. | ||
MiMedx offers 45% modeled upside to its analyst target against just 6.6% downside to its stop-loss, an unusually favorable risk/reward ratio of 4.59x. Targets | The risk/reward ratio should stay well above 3.0x as the price target holds. | →Stable |
| CounterThe stock is down sharply from its 52-week high, a drawdown the engine flags as part of its speculative suitability classification, so the favorable ratio partly reflects how far the stock has already fallen. | ||
The stock has triggered a death-cross hard block and remains below its 200-day moving average in a confirmed downtrend, though the engine notes improving MACD, consistent with a recovery setup. Chart pattern detection | Price should reclaim its 200-day moving average as the recovery setup plays out. | →Stable |
| CounterA death-cross hard block is a significant technical warning, and improving MACD alone has not yet been sufficient to reverse the confirmed downtrend. | ||
MiMedx has beaten EPS estimates in 3 of its last 4 quarters, with an average surprise of about 44.7%. Earnings | The beat streak should continue at the next earnings print. | ↓Deteriorating |
| CounterWith growth weak and revenue declining sharply, EPS beats are likely being driven by cost cuts rather than durable revenue growth. | ||
MiMedx's revenue is declining sharply, down 33% YoY, and the Rule of 40 combined growth-plus-margin metric registers a failing reading.
→StableGrowth breakdown
- Expectation
- Revenue growth should turn positive within a few quarters.
CounterStrong cash conversion and a solid Piotroski F-Score of 7 out of 9 suggest the company is still generating cash efficiently even amid the top-line contraction.
MiMedx offers 45% modeled upside to its analyst target against just 6.6% downside to its stop-loss, an unusually favorable risk/reward ratio of 4.59x.
→StableTargets
- Expectation
- The risk/reward ratio should stay well above 3.0x as the price target holds.
CounterThe stock is down sharply from its 52-week high, a drawdown the engine flags as part of its speculative suitability classification, so the favorable ratio partly reflects how far the stock has already fallen.
The stock has triggered a death-cross hard block and remains below its 200-day moving average in a confirmed downtrend, though the engine notes improving MACD, consistent with a recovery setup.
→StableChart pattern detection
- Expectation
- Price should reclaim its 200-day moving average as the recovery setup plays out.
CounterA death-cross hard block is a significant technical warning, and improving MACD alone has not yet been sufficient to reverse the confirmed downtrend.
MiMedx has beaten EPS estimates in 3 of its last 4 quarters, with an average surprise of about 44.7%.
↓DeterioratingEarnings
- Expectation
- The beat streak should continue at the next earnings print.
CounterWith growth weak and revenue declining sharply, EPS beats are likely being driven by cost cuts rather than durable revenue growth.
Per-dimension breakdown
Quality
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.0 |
| ROA | 1.3 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.9 |
| Current ratio | 7.7 |
| FCF quality | 10.0 |
| Moat | 6.1 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 664% FCF/NI
- ▸Rule of 40: -23 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 10.0 |
- ▸Declining revenue: -35%
Momentum
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 2.6 |
| OBV | 10.0 |
| MA position | 1.0 |
| Volume | 2.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.5%/30d — confirmed downtrend
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.1 |
| Analyst rating | 7.3 |
| Price target | 9.9 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 87%
Insider
5.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.8 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.4 |
| quality rank | 6.3 |
| growth rank | 2.3 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.0 |
| support resistance | 7.7 |
| 52w position | 0.0 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.0 |
| days to cover | 2.2 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 6.3 |
| debt equity | 9.7 |
| news risk | 4.0 |
- ▸Elevated put/call: 2.00
Catalyst
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:6.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.0<4.5
Warning (0)
none
Reward-to-Risk
6.07
Upside
+63.0%
Downside
10.4%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -50% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:4.0<4.5) reinforce the read. Current asymmetry R:R is 6.07 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.4, Insider at 5.9, and Value at 5.6; the weakest are Catalyst at 3.5, Risk (lower is worse) at 4.0, and Momentum at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 6.07 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Favorable Risk Reward
Trip ifRisk-reward ratio falls below 2.0, reversing from the current 4.59.
- P2Sharp Revenue Decline
Trip ifRevenue growth rises above 0% YoY, reversing the current -33% decline.
- P3Death Cross Downtrend Recovery
Trip ifPrice rises back above its 200-day moving average, clearing the current death-cross block.
- P4Earnings Beat Streak
Trip ifEPS surprise falls below 0% (a miss) at the next earnings print.